Association of Type of Vaccination Center With Time to Emergency Department Presentation for Acute COVID-19 Infection: An Exploratory Analysis

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2024 Jan 29

PMID 38283444

Authors

Timothy Regan

Walter B Wills

Andrew R Barbera

Pedro E Reyes

Kellcee Jacklin

Dana Crowder

Kathryn Henderson

Brandon Montes

Andrew Bugajski

Affiliations

Soon will be listed here.

Abstract

Objective The objective of this study was to identify potential associations between coronavirus disease 2019 (COVID-19) vaccination center reception location and time to presentation to the emergency department for acute COVID-19 infection. The a priori hypothesis was that there are significant differences in the outcome based on vaccination administration center type. Methods This was a cross-sectional, observational study conducted within a hospital in Lakeland, Florida, between October 2021 and May 2022. Participants were at least 18 years old with confirmed severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) infection and at least two COVID-19 symptoms at enrollment. Patients with prior confirmed COVID-19 diagnosis and hospitalization within 10 days of screening were excluded. Participants were sampled from within the emergency department of the institution. The primary outcome was time to presentation to the emergency department for acute COVID-19 infection since the last vaccination dose from each sampled COVID-19 vaccination center location. Results A total of 93 participants were analyzed. Of these, 48 (52%) participants received COVID-19 vaccination. Participants vaccinated at vaccine clinics demonstrated a significantly longer mean survival time (288.2 (29.9)) compared to other sites. Significant predictors of hospitalization were age (aOR, 1.09, 95%CI 1.02-1.16, p < 0.01), sex (aOR: 10.05, 95%CI 1.52-66.54, p < 0.05), physical function (aOR, 0.90, 95%CI 0.83-0.97, p < 0.01) and number of medications (aOR, 1.34, 95%CI 1.14-1.58, p < 0.001). Conclusions This exploratory analysis highlights the need for further investigation into both characteristics of healthcare institutions and individual-level factors that may play a role in the prolonged prevention of emergency department presentations due to COVID-19 infection. Increased transparency of data regarding practices related to the administration of COVID-19 vaccines across various institutions may be beneficial in further understanding the role of COVID-19 vaccinations in preventing symptomatic disease across local and global communities.

References

Foss C, Ellefsen B . The value of combining qualitative and quantitative approaches in nursing research by means of method triangulation. J Adv Nurs. 2002; 40(2):242-8. DOI: 10.1046/j.1365-2648.2002.02366.x. View

. Guidelines for maintaining and managing the vaccine cold chain. MMWR Morb Mortal Wkly Rep. 2003; 52(42):1023-5. View

Kis Z . Stability Modelling of mRNA Vaccine Quality Based on Temperature Monitoring throughout the Distribution Chain. Pharmaceutics. 2022; 14(2). PMC: 8877932. DOI: 10.3390/pharmaceutics14020430. View

Erinc Z, Eliacik K, Ince G, Kilic Ozturk Y, Elmali F, Emir B . Understanding Vaccine Hesitancy: Social Isolation in Relation to Social Media Addiction and COVID-19 Anxiety. Cureus. 2022; 14(9):e29705. PMC: 9616316. DOI: 10.7759/cureus.29705. View

Menni C, Valdes A, Polidori L, Antonelli M, Penamakuri S, Nogal A . Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study. Lancet. 2022; 399(10335):1618-1624. PMC: 8989396. DOI: 10.1016/S0140-6736(22)00327-0. View

Kaat A, Buckenmaier 3rd C, Cook K, Rothrock N, Schalet B, Gershon R . The expansion and validation of a new upper extremity item bank for the Patient-Reported Outcomes Measurement Information System® (PROMIS). J Patient Rep Outcomes. 2019; 3(1):69. PMC: 6879697. DOI: 10.1186/s41687-019-0158-6. View

Manry J, Bastard P, Gervais A, Le Voyer T, Rosain J, Philippot Q . The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies. Proc Natl Acad Sci U S A. 2022; 119(21):e2200413119. PMC: 9173764. DOI: 10.1073/pnas.2200413119. View

Fang X, Li S, Yu H, Wang P, Zhang Y, Chen Z . Epidemiological, comorbidity factors with severity and prognosis of COVID-19: a systematic review and meta-analysis. Aging (Albany NY). 2020; 12(13):12493-12503. PMC: 7377860. DOI: 10.18632/aging.103579. View

von Elm E, Altman D, Egger M, Pocock S, Gotzsche P, Vandenbroucke J . The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007; 147(8):573-7. DOI: 10.7326/0003-4819-147-8-200710160-00010. View

10.

Pires C . Global Predictors of COVID-19 Vaccine Hesitancy: A Systematic Review. Vaccines (Basel). 2022; 10(8). PMC: 9415631. DOI: 10.3390/vaccines10081349. View

11.

Kricorian K, Civen R, Equils O . COVID-19 vaccine hesitancy: misinformation and perceptions of vaccine safety. Hum Vaccin Immunother. 2021; 18(1):1950504. PMC: 8920251. DOI: 10.1080/21645515.2021.1950504. View

12.

Lopez Bernal J, Andrews N, Gower C, Robertson C, Stowe J, Tessier E . Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 2021; 373:n1088. PMC: 8116636. DOI: 10.1136/bmj.n1088. View

13.

Thomas S, Moreira Jr E, Kitchin N, Absalon J, Gurtman A, Lockhart S . Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. N Engl J Med. 2021; 385(19):1761-1773. PMC: 8461570. DOI: 10.1056/NEJMoa2110345. View

14.

Zigmond A, SNAITH R . The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983; 67(6):361-70. DOI: 10.1111/j.1600-0447.1983.tb09716.x. View

15.

Schoenmaker L, Witzigmann D, Kulkarni J, Verbeke R, Kersten G, Jiskoot W . mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability. Int J Pharm. 2021; 601:120586. PMC: 8032477. DOI: 10.1016/j.ijpharm.2021.120586. View

16.

Awijen H, Ben Zaied Y, Nguyen D . Covid-19 vaccination, fear and anxiety: Evidence from Google search trends. Soc Sci Med. 2022; 297:114820. PMC: 8847077. DOI: 10.1016/j.socscimed.2022.114820. View

17.

Baden L, El Sahly H, Essink B, Kotloff K, Frey S, Novak R . Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2020; 384(5):403-416. PMC: 7787219. DOI: 10.1056/NEJMoa2035389. View

18.

Delamater P, Leslie T, Yang Y . Examining the spatiotemporal evolution of vaccine refusal: nonmedical exemptions from vaccination in California, 2000-2013. BMC Public Health. 2018; 18(1):458. PMC: 5913803. DOI: 10.1186/s12889-018-5368-y. View

19.

Wen C, Chen Y . Sample size determination for semiparametric analysis of current status data. Stat Methods Med Res. 2018; 28(8):2247-2257. DOI: 10.1177/0962280218761493. View

20.

Bell K, Hogue C, Manning C, Kendal A . Risk factors for improper vaccine storage and handling in private provider offices. Pediatrics. 2001; 107(6):E100. DOI: 10.1542/peds.107.6.e100. View